Climb Bio (CLYM) Competitors $1.28 +0.02 (+1.59%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. PRME, BNTC, HUMA, AMRN, AARD, AURA, HRTX, OLMA, AQST, and PRTAShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Prime Medicine (PRME), Benitec Biopharma (BNTC), Humacyte (HUMA), Amarin (AMRN), Aardvark Therapeutics (AARD), Aura Biosciences (AURA), Heron Therapeutics (HRTX), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Prime Medicine Benitec Biopharma Humacyte Amarin Aardvark Therapeutics Aura Biosciences Heron Therapeutics Olema Pharmaceuticals Aquestive Therapeutics Prothena Climb Bio (NASDAQ:CLYM) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Do insiders & institutionals hold more shares of CLYM or PRME? 69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 0.8% of Climb Bio shares are owned by company insiders. Comparatively, 22.9% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is CLYM or PRME more profitable? Climb Bio's return on equity of -43.95% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -43.95% -42.94% Prime Medicine N/A -107.87%-74.97% Which has better valuation & earnings, CLYM or PRME? Climb Bio has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$2.38-0.54Prime Medicine$3.85M107.88-$198.13M-$1.61-1.96 Does the media refer more to CLYM or PRME? In the previous week, Prime Medicine had 2 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for Prime Medicine and 1 mentions for Climb Bio. Prime Medicine's average media sentiment score of 0.51 beat Climb Bio's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CLYM or PRME? Climb Bio presently has a consensus price target of $9.00, suggesting a potential upside of 603.13%. Prime Medicine has a consensus price target of $10.08, suggesting a potential upside of 219.09%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, CLYM or PRME? Climb Bio has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. SummaryPrime Medicine beats Climb Bio on 8 of the 14 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.14M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.5421.5627.4020.24Price / SalesN/A274.65418.19125.29Price / CashN/A41.9536.6357.47Price / Book0.417.518.085.67Net Income-$73.90M-$55.05M$3.16B$248.47M7 Day Performance8.47%4.59%2.81%3.29%1 Month Performance-0.78%4.86%3.69%5.18%1 Year PerformanceN/A5.82%35.30%21.35% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.8456 of 5 stars$1.28+1.6%$9.00+603.1%N/A$85.14MN/A-0.549Positive NewsPRMEPrime Medicine3.5882 of 5 stars$2.65+9.5%$10.08+280.5%-40.8%$347.93M$3.85M-1.29234Gap UpBNTCBenitec Biopharma1.732 of 5 stars$12.35-6.2%$23.83+93.0%+48.6%$345.46M$80K-8.1820High Trading VolumeHUMAHumacyte2.3808 of 5 stars$2.22+1.4%$11.71+427.7%-60.1%$339.71M$1.57M-3.22150AMRNAmarin0.9333 of 5 stars$15.90-1.8%$12.00-24.5%+18.0%$335.25M$228.61M-4.37360AARDAardvark TherapeuticsN/A$13.86-9.9%$31.25+125.5%N/A$333.68MN/A0.0018Analyst RevisionGap UpAURAAura Biosciences1.7459 of 5 stars$6.29-4.3%$22.00+249.8%-4.5%$330.27MN/A-3.3150HRTXHeron Therapeutics3.9787 of 5 stars$2.16+0.5%$5.00+131.5%-21.8%$328.01M$144.29M-36.00300OLMAOlema Pharmaceuticals1.7743 of 5 stars$4.56-4.0%$24.50+437.3%-58.8%$325MN/A-2.2770AQSTAquestive Therapeutics1.613 of 5 stars$3.25flat$10.14+212.1%+54.4%$322.82M$57.56M-5.51160PRTAProthena2.8044 of 5 stars$6.18+3.2%$31.50+409.7%-67.8%$322.42M$135.16M-2.97130High Trading Volume Related Companies and Tools Related Companies Prime Medicine Competitors Benitec Biopharma Competitors Humacyte Competitors Amarin Competitors Aardvark Therapeutics Competitors Aura Biosciences Competitors Heron Therapeutics Competitors Olema Pharmaceuticals Competitors Aquestive Therapeutics Competitors Prothena Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
